title: Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?
abstract: In the last 15 years, the use of Stereotactic Ablative Radiation Therapy (SABRT) in the management of small peripheral lung tumours has developed considerably, so that it currently represents a standard of care for inoperable stage I non-small cell lung cancer (NSCLC), offering a survival advantage over traditional radiotherapy, local control rates at 3 years around 90%, with a low risk of toxicity. Indications have extended to larger tumours up to 5 cm and centrally located tumours. In this review we will explore the role of SABRT in early stage NSCLC, the state of the art, the challenges and the future for this technique. There are ongoing studies to optimize such approaches within a multicentric setting. Trials comparing surgery to SABRT in operable or marginally operable have failed because of poor accrual. Several questions remain that need to be addressed in prospective studies.
authors: 1 Department of Radiation Oncology, 2 Medical Physics Unit, Gustave Roussy, Université Paris Sud, Villejuif, France.
authors: Almudena
authors: A
authors: Cascales
authors: 1 Department of Radiation Oncology, 2 Medical Physics Unit, Gustave Roussy, Université Paris Sud, Villejuif, France.
authors: Florent
authors: F
authors: Martinetti
authors: 1 Department of Radiation Oncology, 2 Medical Physics Unit, Gustave Roussy, Université Paris Sud, Villejuif, France.
authors: Deborah
authors: D
authors: Belemsagha
authors: 1 Department of Radiation Oncology, 2 Medical Physics Unit, Gustave Roussy, Université Paris Sud, Villejuif, France.
authors: Cecile
authors: C
authors: Le Pechoux
keywords: Non-small cell lung cancer (NSCLC); early lung cancer; radiotherapy; stereotactic radiotherapy